Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LRX712 intra-articular injections for knee osteoarthritis
NL-OMON52598Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LRX712 in knee osteoarthritis (OA) and osteoarthritis (OA) (3 arms), sponsored by Novartis. Primary endpoint: Change in medial femoral condyle cartilage volume. Started Jul 2020; status: completed.
02
Drugs
LRX712
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON52598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52598.